de Jesús Ascencio-Montiel, 28,048 patient aspirin early treatment study: 59% lower combined mortality/hospitalization [p<0.0001], 15% lower mortality [p=0.16], 9% lower ventilation [p=0.51], and 48% lower hospitalization [p<0.0001] https://c19p.org/dejesusascenciomontiele
copied to clipboard
A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
et al., Archives of Medical Research, doi:10.1016/j.arcmed.2022.01.002
Retrospective 28,048 COVID+ patients in Mexico, 7,898 receiving a treatment kit including low dose ivermectin, AZ, aspirin, and acetaminophen, shower lower mortality/hospitalization for those receiving the kit. Delivery of the treatment kit was based on availability in the medical units. Adherence is unknown and may be low. Adjusted results are only provided for combined mortality/hospitalization.
|
risk of death/hospitalization, 59.0% lower, RR 0.41, p < 0.001, treatment 7,898, control 20,150, adjusted per study, multivariable, primary outcome.
|
|
risk of death/hospitalization, 71.0% lower, RR 0.29, p < 0.001, treatment 5,557, control 12,526, adjusted per study, with phone call followup, multivariable.
|
|
risk of death, 15.0% lower, RR 0.85, p = 0.16, treatment 101 of 7,898 (1.3%), control 303 of 20,150 (1.5%), NNT 445, unadjusted, excluded in exclusion analyses:
unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
|
|
risk of mechanical ventilation, 9.1% lower, RR 0.91, p = 0.51, treatment 77 of 7,898 (1.0%), control 216 of 20,150 (1.1%), NNT 1031, unadjusted, excluded in exclusion analyses:
unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
|
|
risk of hospitalization, 47.6% lower, RR 0.52, p < 0.001, treatment 485 of 7,898 (6.1%), control 2,360 of 20,150 (11.7%), NNT 18, unadjusted, excluded in exclusion analyses:
unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
|
|
risk of progression, 41.8% lower, RR 0.58, p < 0.001, treatment 435 of 7,898 (5.5%), control 1,906 of 20,150 (9.5%), NNT 25, unadjusted, ER, excluded in exclusion analyses:
unadjusted results with alternate outcome adjusted results showing significant changes with adjustments.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in meta
analysis:
combined treatments may contribute more to the effect seen.
de Jesús Ascencio-Montiel et al., 1/24/2022, retrospective, Mexico, North America, peer-reviewed, 10 authors, this trial uses multiple treatments in the treatment arm (combined with AZ, acetaminophen, ivermectin) - results of individual treatments may vary.
dejesusascenciomontiel
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.